80043672 - What's New in Diabetic Retinopathy and Venous Occlusive Disease?

What's New in Diabetic Retinopathy and Venous Occlusive Disease? Banner


Date & Location
Friday, October 27, 2017 6:00 AM - 5:00 PM   Johns Hopkins Tilghman Room, Baltimore, MD

Overview

The total number of people worldwide with diabetes mellitus is projected to rise from 171 million in 2000 to 366 million in 2030. In the United States, almost 24 million or 8 percent of the population has diabetes mellitus. Approximately 4.0 million Americans age 40 and older have diabetic retinopathy, 900,000 of whom have vision threatening disease, defined as pre-proliferative retinopathy, macular edema, or both. Diabetic retinopathy remains the leading cause of blindness in adults who make up the work force. Despite this, diabetic retinopathy and venous occlusive disease are often under-diagnosed and under-treated. This annual course highlights new information being reported by the Diabetic Retinopathy Clinical Research Network and others, which will impact current standard care and management strategies.

Who Should Attend

This activity is intended for ophthalmologists, retina specialists, residents, fellows and other health care professionals.



Objectives

After attending this activity, the participant will demonstrate the ability to –

  1. Summarize the evidence of relation of diabetic control to incidence and severity of retinopathy.
  2. Diagnose diabetic macular edema , severe non-proliferative diabetic retinopathy, and high risk proliferative diabetic retinopathy.
  3. Determine how best to manage diabetic macular edema , severe non-proliferative diabetic retinopathy, and high risk proliferative diabetic retinopathy.
  4. Recognize new experimental treatment options.

Accreditation

The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
The Johns Hopkins University School of Medicine designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Maryland Board of Examiners in Optometry has approved this program for 7 Therapeutic hours.